The other treatments for osteoporosis in middle-aged and elderly women

doi:10.7504/fk2014040109

Abstract

Abstract:

Abstract:Osteoporosis (OP) is a chronic degenerative disease that serious damage to the life quality of the older people. The prevalence of women is significantly higher than men,clearly associated with a lack of estrogen in postmenopausal women.Therefore,hormone replacement therapy (HRT) is the first choice for prevention and treatment of osteoporosis in postmenopausal women.But the HRT acceptance rate is only 1%-2% among Chinese women,mainly due to their fear of adverse reactions.Thus,women with postmenopausal osteoporosis who do not take HRT or have HRT contraindications need other options for treatment including selective estrogen receptor modulators,biophosphonates,calcitonin,parathyroid hormone,strontium and Vitamin K.

Key words: osteoporosis, selective estrogen receptor modulators, biophosphonates, calcitonin, parathyroid hormone, strontium, Vitamin K

摘要：

激素补充治疗（hormone replacement therapy，HRT）是预防和治疗绝经后女性骨质疏松症（osteoporosis， OP）的一线治疗方案，但是中国女性HRT接受率仅1%~2%，主要原因是担心其不良反应的发生。因此，对于不愿意接受HRT或者有HRT禁忌证的绝经后骨质疏松症女性患者，可以用非激素类药物如选择性雌激素受体调节剂、双膦酸盐、降钙素、甲状旁腺激素、锶盐、维生素K等。

关键词: 骨质疏松症, 选择性雌激素受体调节剂, 双膦酸盐, 降钙素, 甲状旁腺激素, 锶盐 , 维生素K

CLC Number:

R711

MA Ying. The other treatments for osteoporosis in middle-aged and elderly women[J]. Acta Metallurgica Sinica, DOI: 10.7504/fk2014040109.

马颖. 中老年女性骨质疏松症的其他治疗方法[J]. 中国实用妇科与产科杂志, DOI: 10.7504/fk2014040109.

References

[1］ Cummings SR,Eckert S,Krueger KA,et al.The effect of raloxifene on risk of breast cancer in postmenopaus women:results from the MORE randomized trial[J].JAMA,1999,281(23):2189-2197.

[2］ Barrett-Connor E,Mosca L,Collins P,et al.Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women[J].N Engl J Med,2006,355(2):125-137.

[3］ Barrett-Connor E,Grady D,Sashegyi A,et al.Raloxifene and ardiovascular events in osteoporotic postmenopausal women:four-year results from the MORE(Multiple Outcomes of Raloxifene Evaluation) randomized trial[J].JAMA,2002,287(7):847-857. 

[4］ Pinkerton JV,Goldstein SR.Endometrial safety:a key hurdle for selective estrogen receptor modulators in development[J].Menopause,2010,17(3):642-653.

[5］ Liao H,Li F.Current Status of Bisphosphonates in the Inhibit of Bone Loss [J]. Orthopaedic Biomechanics Materials and Clinical Study,2004,1(1): 20-24.

[6］ Maksmowych WP.Managing acute osteoporotic vertebral fractures with caltitonin[J].Can Fam Physician,1998,44:2160-2166. 

[7］ Morley P,Whitfield F,Willick E.Anabolic effects of parathyroid hormone on bone[J].Trend Endocrinol Metab,1997,8(6):225-231.

[8］ Ma YL,Cain RI,Halladay DI,et al. Catabolic effects of continuous human PTH(1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoporotegerin and gene-associated bone formation[J]. Endocrinology,2001,142:4047-4054.

[9］ Miller PD.Safety of parathyroid hormone for the treatment of osteoporosis [J]. Curr Osteoporos Rep,2008,6(1):12-16.

[10］ Pors Nielsen S. The biological role of strontium [J]. Bone,2004,35 (3) :583-588.

[11］ Fonseca JE. Rebalancing bone turnover in favour of bone f ormation with strontium ranelate: implication for bone strength [J]. Rheumatology,2008,47:17-19.

[12］ Reginster JY,Seeman E,De Vernejoul MC,et al. Strontium ranelate reduces the risk of nonvertebral fracture in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOP) study[J]. J Clin Endocrinol Metab,2005,90(5): 2816-2822.

[13］ Reginster JY,Felsenberg D,Boonen S,et al. Effect of long- term strontium ranelate treatment on the risk of nonvertebral and vertebral fracture in postmenopausal osteoporosis: resultof a Five-Year,randomized,placebo-contrlled trial[J].Arthritis Rheum,2008,58(6): 1687-1695.

[14］中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南（2011年）[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17.

[1]	PENG Hong-fa，YAN Xiao-nan. Menopausal hormone therapy and osteoporosis. [J]. Acta Metallurgica Sinica, 2020, 36(3): 230-233.
[2]	LEI Xiao-min，TAN Xin-sha. Effects of premature ovarian insufficiency on bone metabolism [J]. Acta Metallurgica Sinica, 2018, 34(3): 245-248.
[3]	. 原发性骨质疏松的共同特点为在骨代谢过程中,骨吸收和骨形成之间出现失衡，病因复杂，发病机制与遗传、内分泌紊乱、营养不均衡和废用等有关。现综述如下。 1 遗传因素家系和双胞胎研究表明骨质疏松有很强的遗传倾向。遗传因素在骨量和骨强度的获得上起重要作用。基因的多态性与骨代谢的差异有着密切的关系，并且是由多个候选基因而非单一基因共同影响的。近年来有关基因研究较多并得到人们关注的候选基因主要有维生素D受体(vitamin D receptor,VDR)基因、雌激素受体(estrogen receptor,ER)基因、Ⅰ型胶原基因及一些生长因子基因。 1. [J]. Acta Metallurgica Sinica, 2014, 30(5): 379-382.
[4]	YU Qi. More attention should be paid to menopause related osteoporosis. YU Qi [J]. Acta Metallurgica Sinica, 2014, 30(5): 321-322.
[5]	JIANG Jian-fa,SUN Ai-jun. Epidemiology,classification and diagnosis of osteoporosis in middle-aged women [J]. Acta Metallurgica Sinica, 2014, 30(5): 323-326.
[6]	ZOU Shi-En,ZHANG Shao-Fen. Phytoestrogens and osteoporosis of middle-aged and elderly women [J]. Acta Metallurgica Sinica, 2014, 30(5): 329-333.
[7]	XU Ling. Menopausal hormone therapy and osteoporosis in midlife and postmenopausal women [J]. Acta Metallurgica Sinica, 2014, 30(5): 333-336.
[8]	HUANG Qi-ren. Calcium,Vitamin D and osteoporosis [J]. Acta Metallurgica Sinica, 2014, 30(5): 336-340.
[9]	TAN Yong. TCM prevention and treatment strategies of middle-aged women with osteoporosisTCM prevention and treatment strategies of middle-aged women with osteoporosis [J]. Acta Metallurgica Sinica, 2014, 30(5): 340-343.
[10]	ZOU Jun. Exercise in the treatment and prevention of osteoporosis in elderly women [J]. Acta Metallurgica Sinica, 2014, 30(5): 343-347.
[11]	. [J]. Acta Metallurgica Sinica, 2014, 30(5): 379-382.
[12]	. [J]. Acta Metallurgica Sinica, 2014, 30(5): 383-386.